| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
Matrix metalloproteinases (MMP) are a family of enzymes that selectively digest individual components of the extracellular matrix. Their function has been studied in both normal physiologic processes and pathologic states. In the blood vessel, MMPs play an important role in maintaining the vessel's integrity by breaking down extracellular matrix while new matrix is being synthesized. This is necessary to avoid weakening from continuous mechanical stresses. However, in certain environments, these MMPs may contribute to cardiovascular pathologic processes. The purpose of this review is to first discuss the role of MMPs in coronary vascular disease. Evidence suggests that MMPs contribute to the development of de novo atherosclerotic plaques and postangioplasty restenotic plaques by allowing smooth muscle cells to migrate from the vascular media to the intima. Evidence also suggests that MMPs contribute to the rupture of these plaques by degrading the fibrous cap that surrounds them. With this increased molecular information that concerns the pathogenesis of coronary vascular disease, new molecular therapies aimed at altering these processes are being investigated. The rationale, mode of delivery, and prospects for success of these therapies will also be discussed here.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  A. H. Thomas, E. R. Edelman, and C. M. Stultz A BRIEF COMMUNICATION: Collagen Fragments Modulate Innate Immunity Experimental Biology and Medicine, March 1, 2007; 232(3): 406 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Merklinger, P. L. Jones, E. C. Martinez, and M. Rabinovitch Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension Circulation, July 19, 2005; 112(3): 423 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aljada, H. Ghanim, P. Mohanty, T. Syed, A. Bandyopadhyay, and P. Dandona Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations Am. J. Clinical Nutrition, July 1, 2004; 80(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Briest, A. Holzl, B. Rassler, A. Deten, H. A Baba, and H.-G. Zimmer Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts Cardiovasc Res, February 1, 2003; 57(2): 379 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Grzeszkiewicz, V. Lindner, N. Chen, S. C.-T. Lam, and L. F. Lau The Angiogenic Factor Cysteine-Rich 61 (CYR61, CCN1) Supports Vascular Smooth Muscle Cell Adhesion and Stimulates Chemotaxis through Integrin {alpha}6{beta}1 and Cell Surface Heparan Sulfate Proteoglycans Endocrinology, April 1, 2002; 143(4): 1441 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Pollanen, P. J. Karhunen, J. Mikkelsson, P. Laippala, M. Perola, A. Penttila, K. M. Mattila, T. Koivula, and T. Lehtimaki Coronary Artery Complicated Lesion Area Is Related to Functional Polymorphism of Matrix Metalloproteinase 9 Gene: An Autopsy Study Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1446 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G Spinale, M. L Coker, B. R Bond, and J. L Zellner Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target Cardiovasc Res, May 1, 2000; 46(2): 225 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-H. Yu and J. F. Woessner Jr. Heparan Sulfate Proteoglycans as Extracellular Docking Molecules for Matrilysin (Matrix Metalloproteinase 7) J. Biol. Chem., February 11, 2000; 275(6): 4183 - 4191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Loscalzo Vascular Matrix and Vein Graft Failure : Is the Message in the Medium? Circulation, January 25, 2000; 101(3): 221 - 223. [Full Text] [PDF]
|
|
|
|
|
|
K. P. Langton, M. D. Barker, and N. McKie Localization of the Functional Domains of Human Tissue Inhibitor of Metalloproteinases-3 and the Effects of a Sorsby's Fundus Dystrophy Mutation J. Biol. Chem., July 3, 1998; 273(27): 16778 - 16781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jiang, K. Lehti, X. Wang, S. J. Weiss, J. Keski-Oja, and D. Pei Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis PNAS, November 20, 2001; 98(24): 13693 - 13698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Chancey, G. L. Brower, J. T. Peterson, and J. S. Janicki Effects of Matrix Metalloproteinase Inhibition on Ventricular Remodeling Due to Volume Overload Circulation, April 23, 2002; 105(16): 1983 - 1988. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
